Sumitomo Dainippon Pharma Oncology, Inc ( SDP Oncology)

Primary tabs

SDP Oncology's picture

Management

**

Contact Address

640 Memorial Drive Cambridge, Massachusetts, US

About Sumitomo Dainippon Pharma Oncology, Inc

Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology, Inc or SDP Oncology. SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer.

SDP Oncology press release, blog etc

Mon, 06/22/2020 - 02:12 Tolero Pharmaceuticals Presents Biomarker Identification Strategies for Investigational Agents Alvocidib and TP-1287 at AACR Virtual Meeting II 2020
Tue, 05/19/2020 - 02:13 Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454
Thu, 05/14/2020 - 08:19 Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)
Wed, 03/25/2020 - 21:35 Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Societys Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia
Tue, 10/29/2019 - 07:06 Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models
Sat, 09/28/2019 - 08:02 Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019
Thu, 06/13/2019 - 21:17 Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019
Wed, 06/12/2019 - 16:52 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Thu, 05/30/2019 - 04:33 Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors
Wed, 05/15/2019 - 21:19 Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019
Mon, 05/13/2019 - 23:01 Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors
Wed, 02/27/2019 - 09:34 Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019
Thu, 01/10/2019 - 07:56 Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors
Sat, 12/01/2018 - 08:49 Tolero Pharmaceuticals to highlight new data evaluating investigational agents Alvocidib and TP-1287 at 2018 American Society of Hematology annual meeting
Sat, 12/01/2018 - 08:00 Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018
Thu, 11/15/2018 - 07:54 Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors
Tue, 10/16/2018 - 08:28 Tolero Pharmaceuticals announces first patient dosed with investigational agent Alvocidib in phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS)
Fri, 08/17/2018 - 09:43 Tolero Pharmaceuticals announces clinical research collaboration with AbbVie for acute myeloid leukemia trial.
more

InfoBox

Formation2020
HeadPatricia S. Andrews
FounderPatricia S. Andrews
Employees500
LocationUnited States
HomePagewww.sdponcology.com
LinkedInwww.linkedin.com/company/sdponcology